Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hormone treatment shows promise for rare adrenal disorder

NCT ID NCT05299554

Completed Disease control Sponsor: Immedica Pharma AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of a medication called Chronocort in 76 people aged 16 and older with congenital adrenal hyperplasia (CAH), a condition where the body can't make enough cortisol. Researchers monitored for signs of over- or under-treatment, adrenal crises, and side effects over time. The goal was to see if Chronocort is safe for ongoing use to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital adrenal hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL ADRENAL HYPERPLASIA

Contacts and locations

Locations

  • National Institutes of Health Center

    Bethesda, Maryland, 20892-1932, United States

  • Neurocrine Investigational Site in Asahi-ku

    Yokohama, Kanagawa, 241-0811, Japan

  • Neurocrine Investigational Site in Caen

    Caen, 14033, France

  • Neurocrine Investigational Site in California

    Los Angeles, California, 90027, United States

  • Neurocrine Investigational Site in California

    Orange, California, 92868, United States

  • Neurocrine Investigational Site in Florida

    Jacksonville, Florida, 32207, United States

  • Neurocrine Investigational Site in Iowa

    Iowa City, Iowa, 52242, United States

  • Neurocrine Investigational Site in Michigan

    Ann Arbor, Michigan, 48114, United States

  • Neurocrine Investigational Site in Minnesota

    Rochester, Minnesota, 55901, United States

  • Neurocrine Investigational Site in Nevada

    Las Vegas, Nevada, 89148, United States

  • Neurocrine Investigational Site in Okura

    Setagaya-Ku, Tokyo, 157-8535, Japan

  • Neurocrine Investigational Site in Paris

    Paris, 75651, France

  • Neurocrine Investigational Site in Pessac

    Pessac, 33604, France

  • Neurocrine Investigational Site in Texas

    Dallas, Texas, 75235, United States

  • Neurocrine Investigational Site in Toulouse

    Toulouse, 31059, France

  • Neurocrine Investigational Site in Toulouse (Children's hospital)

    Toulouse, 31059, France

  • Neurocrine Investigational Site in Toyama

    Shinjuku-Ku, Tokyo, 162-8655, Japan

  • Neurocrine Investigational Site in Washington

    Seattle, Washington, 98105, United States

  • Neurocrine Investigational Site in Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Neurocrine Investigational Site in Yushima

    Bunkyō-Ku, Tokyo, 113-8519, Japan

  • Neurocrine investigational Site in Lyon

    Lyon, 69677, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.